John Thero

18 results

Vascepa – which will be sold as Vazkepa in Europe – reduces harmful blood fats called triglycerides in patients at risk of potentially fatal heart attack or stroke.

Amarin, the Irish biotech that developed a cardiovascular drug out of refined fish oil, is gearing up for a launch in Europe. It will be a further va(...)

Shares in cardiovascular drugmaker Amarin slumped over 70% last night as the company lost a key patent case in Nevada.

Shares in Irish heart drug company Amarin slumped more than 70 per cent last night as the company lost a key court case in Nevada over the patents of (...)

Irish drug company Amarin says sales from Vascepa, its one cardiovascular drug for 2019, will be at or above the upper end of its previous guidance

Irish drug company Amarin says sales from its one cardiovascular drug for 2019 will be at or above the upper end of its previous guidance – indicating(...)

Noel and Valerie Moran walked away with a €266 million payout for Prepaid Financial Service. Photograph: Alan Betson

It was a year of extremes in the corporate world – financial reward and glory for some; the end of the road for others. And 2019 also saw a cast of fi(...)

Amarin’s Vascepa has been found to reduce the risk of cardiovascular events in high-risk patients already being treated with statins.

Amarin, the US-based Irish drug development business, said the European Medicines Agency has accepted an application to licence its cardiovascular dru(...)

Amarin’s John Thero:  “Breakthroughs in preventative cardiovascular care are rare and greatly needed.” Photograph: Cyril Byrne

John Thero, the president and chief executive of fish-oil drug specialist Amarin, has been awarded the EY Entrepreneur of the Year award in the US for(...)

Vascepa is aiming to become the first prescription drug for people at risk of stroke or heart attack who continue to have high levels of harmful blood fats despite being on treatment with statins

Shares in US-listed Irish biotech Amarin surged in New York after it upgraded its profit forecasts. A strong update for the prospects of its cardiova(...)

John Thero: ‘I am pleased that Amarin’s significant progress and innovative work is recognised by this award.’ Photograph: Cyril Byrne

Fish oil drug specialist Amarin has been recognised for the breakthrough results for its one medicine, Vascepa, as a cardiovascular therapy. John The(...)

The FDA grants priority review only to drugs that have the potential to offer significant improvement in the treatment of serious conditions.

Shares in Irish drug company Amarin jumped 14 per cent after its Vascepa drug was fast-tracked for approval as a treatment for reducing the risk of he(...)

US FDA approval would allow Amarin to pitch its fish-oil drug direct to the consumer rather than solely through the medical practitioner channel. File photograph: Getty

Shareholders tuning into Amarin’s annual shareholders’ meeting in Dublin on Monday had plenty to cheer them. Shares in the company have risen more th(...)

  • 1
  • 2
  • Next
  • Last »